Dr Derek Yach’s Nicotine 2030, published earlier this month in conjunction with Zanoprima Lifesciences, a developer of synthetic nicotine, pulls together much of the evidence that has built up in recent years on smoke-free nicotine, global health and regulation. We read it with particular interest because Dr Yach chairs our Harm Reduction Stewardship Council and writes with real standing in this field: as a former Executive Director at the World Health Organization, he played a leading role in developing the Framework Convention on Tobacco Control, still the foundation of global tobacco policy.
The central finding is striking: if 20% of the world’s roughly one billion smokers were to switch to verified low-risk nicotine products within fifteen years, Dr Yach’s modelling suggests around 100m premature deaths could be averted by 2060 — on top of the gains from conventional tobacco control. The figure is an estimate, not a forecast, and the report is open about its assumptions. But the direction fits our own view: that the transformation of this industry is a major opportunity for global public health and, handled responsibly, for investors too.
The evidence has moved; policy has been slower
The scientific evidence in favour of tobacco harm reduction continues to build. The report notes that smoke-free products expose users to dramatically lower levels of harmful chemicals than cigarettes – in many cases a small fraction of those found in smoke – and that recent Cochrane and Addiction reviews find consistent evidence of e-cigarettes outperforming traditional nicotine-replacement therapy for cessation. As Dr Yach puts it, ‘the enemy is smoke, not nicotine’.
But regulation has often gone the other way. Across several of the largest markets the instinct has been to restrict rather than to regulate in proportion to risk — and prohibition has a habit of redirecting demand rather than removing it, often toward something worse. India is the clearest example: its 2019 ban on e-cigarettes closed off a lower-risk option while consumption of gutkha — a hazardous smokeless tobacco product strongly linked to oral cancer — rose sharply, with rural household use rising more than fivefold between 2011–12 and 2023–24. Bans rarely remove demand; more often they push it into unregulated channels, with no quality control, no youth protection and no tax revenue.
The contrast between markets
The report draws weight from the divergence between markets that have made room for harm reduction and those that haven’t. Dr Yach points to Sweden, where decades of snus and more recent nicotine-pouch use accompanied a fall in adult daily smoking below 5%; to Japan, where rapid uptake of heated tobacco coincided with a 52% decline in cigarette sales between 2014 and 2023; and to the United Kingdom, where over 2m ex-smokers had switched to vaping by 2024. These are population-level observations rather than controlled experiments, but taken together they are hard to dismiss.
Why this matters for investors — and why policy is the missing piece
At Hexis we favour investors engaging with industry rather than divesting, and the report reinforces why. It describes an industry already some way into transformation: certain companies have taken big strides, with smoke-free products now a substantial and growing share of their revenues, while others lag well behind. That gap is exactly where engaged, long-term shareholders can have some influence — pressing for capital to flow toward reduced-risk products, for credible targets, and for open and transparent discussion of progress and challenges.
But companies can only do so much on their own. The most important point in the report is that the health benefits of transformation will only be fully realised if governments put the right policies in place. Risk-proportionate regulation — quality standards instead of bans, and taxation that tracks the wide differences in risk between combustible and reduced-risk products — is what lets people who smoke move toward legally-available less harmful products rather than stick to cigarettes or turn to illicit markets. The report is encouraging here too: bodies such as the IMF and the reinsurer Swiss Re have started to reflect the risk continuum in how they think about taxation and the underwriting of smoking risk.
Conclusions
Nicotine 2030 won’t settle a debate that remains, as Dr Yach acknowledges, as much about ideology as science, and it shouldn’t be read as a guarantee of any outcome. What it does is set out the case that the means to avert a large share of the world’s smoking deaths already exist, and that the main barriers now are political rather than scientific. For investors willing to engage rather than walk away, and for governments willing to regulate in proportion to risk, that is an opportunity worth taking seriously.

